Switching from Ozempic to Wegovy: what the evidence says

Why the same molecule needs two separate prescriptions

Semaglutide was first authorised in the UK under the brand name Ozempic to treat type 2 diabetes, at doses up to 1 mg weekly. Wegovy came later, studied at the higher 2.4 mg dose in dedicated weight-management trials, most prominently STEP 1, published in the New England Journal of Medicine, which found an average body-weight reduction of around 15% over 68 weeks. Because the evidence base, the dose and the licensed population differ, the two products are treated as distinct by the MHRA, even though the active ingredient is the same.

This matters practically: a prescriber writing for Wegovy is authorising it within a weight-management framework, which typically involves monitoring, lifestyle support and defined stopping rules. One issued by a diabetes team for Ozempic sits within a glycaemic-control framework with different review points. The NHS semaglutide medicines page notes both uses but keeps the clinical pathways clearly separate.

So when people ask whether you can change from Ozempic to Wegovy, the honest answer is: the molecule travels with you, but the prescribing context has to be rebuilt from scratch. Worth knowing before any conversation with a prescriber.

What happens to your diabetes management if you make the switch

If Ozempic was prescribed for type 2 diabetes, that clinical need does not disappear when you move to a weight-management pathway. Semaglutide does have blood-glucose-lowering effects at any dose, which is part of why some people with both obesity and diabetes benefit from Wegovy, but the NHS England guidance on weight-management injections is explicit that switching requires careful prescriber oversight, particularly to avoid gaps in glucose control.

Concretely: if your diabetes was managed primarily through Ozempic and you stop it abruptly, blood sugar can rise. A switch to Wegovy would need to be continuous, matched to the right dose equivalent, and tracked by a clinician familiar with both your metabolic history and the Wegovy titration schedule. That schedule starts at 0.25 mg and steps up gradually, your pen lives in the fridge door between weekly doses, and each step upward needs prescriber sign-off rather than self-adjustment.

People without a diabetes diagnosis who were taking Ozempic off-label for weight loss face a different situation: off-label use is not a prescription anyone can simply transfer to a Wegovy prescription, and the receiving prescriber needs to assess from the beginning whether Wegovy's licensed criteria apply to you.

What IS licensed for weight management in the UK, and your options

Two injectable medicines currently hold UK marketing authorisations specifically for weight management. Wegovy (semaglutide, Novo Nordisk) is licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related condition; lower thresholds apply for some ethnic backgrounds under UK clinical guidance. The second is Mounjaro (tirzepatide, Eli Lilly), a dual GIP and GLP-1 receptor agonist licensed under the same broad BMI criteria, and the only medicine of its kind in the UK. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks, a finding reflected in NICE's appraisal discussion. If you're exploring your options after Ozempic, both are worth understanding; our overview of Wegovy and our broader weight-loss treatment page lay out what each involves.

There is also the newly approved oral semaglutide tablet (Wegovy tablet, approved by the MHRA in June 2026) for those who prefer not to inject, though that is a separate prescribing decision from a switch of the injectable. If you want to understand more about the relationship between Ozempic and Wegovy as products, that page covers it in detail.

How a private prescriber can help you navigate the change

At nume, a GPhC-registered Independent Prescriber (not a decision algorithm) personally reviews every consultation the same day it is submitted. For someone moving from Ozempic, that review covers your original clinical history, current dose, and whether a licensed weight-management medicine is appropriate for you now. Evidence of your existing treatment matters: dose increases and switches both require clinical evidence before a new prescription is issued.

The process is the same whether you're curious about moving to Wegovy, comparing it with alternatives, or simply trying to understand your next steps after a diabetes-focused prescription. There are no hidden fees, no automatic renewals, every repeat is reviewed individually. If you want to explore what's right for your situation, the detail on moving from Ozempic covers the process further, and you can read more about how our prescribers approach these decisions on our clinical team page. When you're ready, checking your eligibility is the starting point.